Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lex Wunderink

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Trials|March 24, 2010
A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trialJudith Rietdijk, Sara Dragt, Rianne Klaassen, et al.
The Journal of Nervous and Mental Disease|August 30, 2016
Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis: Findings From a Pilot StudySteven de Jong, Rozanne J M van Donkersgoed, André Aleman, et al.
BMC Psychiatry|February 5, 2014
A manual-based individual therapy to improve metacognition in schizophrenia: protocol of a multi-center RCTRozanne J M Van Donkersgoed, Steven De Jong, Mark Van der Gaag, et al.
Plos One|June 2, 2015
Cognitive alexithymia is associated with the degree of risk for psychosisJorien van der Velde, Marte Swart, Sophie van Rijn, et al.
BMC Psychiatry|December 2, 2017
Identifying levels of general distress in first line mental health services: can GP- and eHealth clients' scores be meaningfully compared?Jan van Bebber, Johanna T W Wigman, Lex Wunderink, et al.
Schizophrenia Bulletin|August 25, 2023
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery ConsortiumSanne Koops, Kelly Allott, Lieuwe de Haan, et al.
Schizophrenia Research|February 4, 2018
Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS)Agna A Bartels-Velthuis, Ellen Visser, Johan Arends, et al.
Schizophrenia Bulletin|September 4, 2012
Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trialMark van der Gaag, Dorien H Nieman, Judith Rietdijk, et al.
Scientific Reports|February 24, 2016
Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS StudyEdith Liemburg, Anita Sibeijn-Kuiper, Leonie Bais, et al.
Psychopharmacology|February 22, 2011
Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medicationJelle Vehof, Arne J Risselada, Asmar F Y Al Hadithy, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Trials|March 24, 2010
A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trialJudith Rietdijk, Sara Dragt, Rianne Klaassen, et al.
The Journal of Nervous and Mental Disease|August 30, 2016
Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis: Findings From a Pilot StudySteven de Jong, Rozanne J M van Donkersgoed, André Aleman, et al.
BMC Psychiatry|February 5, 2014
A manual-based individual therapy to improve metacognition in schizophrenia: protocol of a multi-center RCTRozanne J M Van Donkersgoed, Steven De Jong, Mark Van der Gaag, et al.
Plos One|June 2, 2015
Cognitive alexithymia is associated with the degree of risk for psychosisJorien van der Velde, Marte Swart, Sophie van Rijn, et al.
BMC Psychiatry|December 2, 2017
Identifying levels of general distress in first line mental health services: can GP- and eHealth clients' scores be meaningfully compared?Jan van Bebber, Johanna T W Wigman, Lex Wunderink, et al.
Schizophrenia Bulletin|August 25, 2023
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery ConsortiumSanne Koops, Kelly Allott, Lieuwe de Haan, et al.
Schizophrenia Research|February 4, 2018
Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS)Agna A Bartels-Velthuis, Ellen Visser, Johan Arends, et al.
Schizophrenia Bulletin|September 4, 2012
Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trialMark van der Gaag, Dorien H Nieman, Judith Rietdijk, et al.
Scientific Reports|February 24, 2016
Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS StudyEdith Liemburg, Anita Sibeijn-Kuiper, Leonie Bais, et al.
Psychopharmacology|February 22, 2011
Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medicationJelle Vehof, Arne J Risselada, Asmar F Y Al Hadithy, et al.
Pageof 6